Conference Coverage

Protein expression may predict HBV DNA suppression


 

FROM ILC 2021

Timing of expression patterns

During the question-and-answer session following his presentation, comoderator Pablo Sarobe, MD, from the Clinica Universidad de Navarra (Spain), said: “I’ve seen that you have compared the different proteins which are detected in your cell samples 24 weeks after stopping treatment. Do you think that these differences are already relevant just at the end of treatment, or that these proteins are being expressed [during] the 24 weeks between the end of treatment and your determination?”

“We only have one time-point sample, so it’s hard to say,” Dr. Chan replied, but he speculated that the delay would not have a direct impact on protein expression, “so probably this expression should last after treatment has stopped. But we only have only posttreatment 24-week data, and we believe that some of the outcome measures may change with longer follow-up. After 1 year some patients in suppression may relapse.”

Asked by an audience member whether the investigators had performed a subanalysis of patients treated with nucleoside analogs, Dr. Chan noted that such an analysis was under consideration, although the patient numbers were relatively small. He did add, however, that protein expression patterns differed among patients treated with nucleoside analogs and PEG-IFN.

The study was funded by Gilead Sciences. Dr. Chan disclosed sponsored lecture activities and consulting for Gilead and others. Dr. Sarobe reported no conflicts of interest.

Pages

Recommended Reading

Bathroom blues: Inexpensive dye tracks digestive transit time
MDedge Internal Medicine
COVID-19 vaccinations may be weakened by liver disease
MDedge Internal Medicine
C. difficile guidelines offer new possibilities
MDedge Internal Medicine
Early-onset CRC associated with longer survival
MDedge Internal Medicine
Calories may outweigh nutrients in diets for fatty liver
MDedge Internal Medicine
Worse survival with recurrent AIH after transplant
MDedge Internal Medicine
Novel liver dialysis device may safely curb ACLF
MDedge Internal Medicine
Novel oral inhibitor may block intestinal damage in celiac disease
MDedge Internal Medicine
The pandemic hurt patients with liver disease in many ways
MDedge Internal Medicine
Rapid core antigen HCV tests could expand accessibility
MDedge Internal Medicine